BR112017004141B8 - Agente de imagemamento e seu uso - Google Patents

Agente de imagemamento e seu uso

Info

Publication number
BR112017004141B8
BR112017004141B8 BR112017004141A BR112017004141A BR112017004141B8 BR 112017004141 B8 BR112017004141 B8 BR 112017004141B8 BR 112017004141 A BR112017004141 A BR 112017004141A BR 112017004141 A BR112017004141 A BR 112017004141A BR 112017004141 B8 BR112017004141 B8 BR 112017004141B8
Authority
BR
Brazil
Prior art keywords
imaging agent
imaging
probes
compound
formula
Prior art date
Application number
BR112017004141A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017004141A2 (pt
BR112017004141B1 (pt
Inventor
Dominguez Celia
Wityak John
Bard Jonathan
Kiselyov Alex
John Brown Christopher
René Gabriel GALAN Sébastien
Edward Prime Michael
Richard Giles Paul
Luciennen Paulette GADOULEAU Elise
Martin Krüle Thomas
CLARK-FREW Daniel
David Johnson Peter
Coe Samuel
HAYES Sarah
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of BR112017004141A2 publication Critical patent/BR112017004141A2/pt
Publication of BR112017004141B1 publication Critical patent/BR112017004141B1/pt
Publication of BR112017004141B8 publication Critical patent/BR112017004141B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/0035—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112017004141A 2014-08-29 2015-08-28 Agente de imagemamento e seu uso BR112017004141B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043603P 2014-08-29 2014-08-29
US62/043,603 2014-08-29
PCT/US2015/047407 WO2016033445A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (3)

Publication Number Publication Date
BR112017004141A2 BR112017004141A2 (pt) 2017-12-12
BR112017004141B1 BR112017004141B1 (pt) 2022-04-19
BR112017004141B8 true BR112017004141B8 (pt) 2022-08-02

Family

ID=55400648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004141A BR112017004141B8 (pt) 2014-08-29 2015-08-28 Agente de imagemamento e seu uso

Country Status (20)

Country Link
US (3) US10479802B2 (OSRAM)
EP (2) EP3186233B8 (OSRAM)
JP (2) JP6817207B2 (OSRAM)
KR (2) KR102586736B1 (OSRAM)
CN (2) CN116655618B (OSRAM)
AU (1) AU2015308774B2 (OSRAM)
BR (1) BR112017004141B8 (OSRAM)
CA (1) CA2959501C (OSRAM)
DK (1) DK3186233T3 (OSRAM)
EA (1) EA035646B1 (OSRAM)
ES (1) ES2898965T3 (OSRAM)
HR (1) HRP20211778T1 (OSRAM)
HU (1) HUE056957T2 (OSRAM)
IL (1) IL250803B (OSRAM)
MX (2) MX380810B (OSRAM)
PL (1) PL3186233T3 (OSRAM)
PT (1) PT3186233T (OSRAM)
SG (1) SG11201701600QA (OSRAM)
SI (1) SI3186233T1 (OSRAM)
WO (1) WO2016033445A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10907197B2 (en) 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
PT3186241T (pt) 2014-08-29 2021-01-08 Chdi Foundation Inc Sondas para imagística de proteína de huntington
CA2959501C (en) 2014-08-29 2023-10-10 Chdi Foundation, Inc. Probes for imaging huntingtin protein
KR102410733B1 (ko) 2014-08-29 2022-06-20 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴 단백질을 영상화하기 위한 프로브
RU2721419C2 (ru) 2015-08-28 2020-05-19 СиЭйчДиАй ФАУНДЕЙШН, ИНК. Зонды визуализации белка гентингтина
RU2766139C2 (ru) 2016-03-11 2022-02-08 Ац Иммуне Са Бициклические соединения для диагностики и лечения
CN107056723A (zh) * 2017-04-21 2017-08-18 云南大学 一种具有抑制血管内皮生长因子受体信号传导的化合物
CA3075892C (en) 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases
WO2019201921A1 (de) 2018-04-20 2019-10-24 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
SG11202012150UA (en) 2018-06-08 2021-01-28 Ac Immune Sa Novel compounds for diagnosis
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
US11389438B2 (en) 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
CN111635400A (zh) 2019-03-02 2020-09-08 察略盛医药科技(上海)有限公司 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
US11992535B2 (en) * 2019-12-18 2024-05-28 Chdi Foundation, Inc. Compounds and probes for imaging huntingtin protein
CN115209952B (zh) 2020-01-13 2025-05-30 维基分析有限公司 经取代的吡唑并嘧啶及其用途
CA3175602A1 (en) 2020-05-07 2021-11-11 Jerome Molette Novel compounds for diagnosis
US12036292B2 (en) * 2020-08-06 2024-07-16 Chdi Foundation, Inc. Heterobiaryl compounds and imaging agents for imaging huntingtin protein
CN117412960A (zh) * 2021-04-08 2024-01-16 Chdi基金会股份有限公司 用于对亨廷顿蛋白成像的异吲哚啉酮化合物和显像剂
CN117545512A (zh) * 2021-04-27 2024-02-09 Chdi基金会股份有限公司 用于对亨廷顿蛋白成像的氘化化合物和成像剂
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
US20250034149A1 (en) 2021-11-10 2025-01-30 Ac Immune Sa Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis
AU2022385416A1 (en) 2021-11-10 2024-05-02 Ac Immune Sa 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis
US20250042905A1 (en) 2021-11-10 2025-02-06 Ac Immune Sa Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
TW202425965A (zh) 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
EP4634191A1 (en) 2022-12-16 2025-10-22 AC Immune SA Novel compounds for diagnosis
WO2024126840A1 (en) 2022-12-16 2024-06-20 Ac Immune Sa Novel compounds for diagnosis
TW202500134A (zh) * 2023-05-18 2025-01-01 美商恩維達醫療公司 G-蛋白偶聯受體之拮抗劑
WO2025037013A1 (en) 2023-08-16 2025-02-20 Ac Immune Sa Diagnostic compounds that bind to alpha-synuclein
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same
CN119264072B (zh) * 2024-12-06 2025-05-02 国科大杭州高等研究院 对细胞成像的荧光探针及其合成方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985755A (en) 1972-06-02 1976-10-12 E. R. Squibb & Sons, Inc. Pyridine containing isothiocyanobenzoxazoles
US4198416A (en) 1976-09-30 1980-04-15 Meiji Seika Kaisha, Ltd. 5-Alkoxy-picolinic esters and anti-hypertensive composition containing 5-alkoxy-picolinic esters
DE2909754A1 (de) * 1979-03-13 1980-09-18 Thomae Gmbh Dr K Neue benzofuran- und benzothiophenderivate, deren herstellung und deren verwendung als arzneimittel
FR2524468B1 (fr) 1982-04-06 1985-10-18 Sandoz Sa Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
GB9317949D0 (en) * 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
PT729956E (pt) 1995-02-28 2002-03-28 Lilly Co Eli Compostos intermediarios formulacoes e metodos de benzotiofeno
JPH08325265A (ja) * 1995-05-29 1996-12-10 Fujisawa Pharmaceut Co Ltd チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物
EP0880519B1 (en) 1996-01-22 2002-04-17 Fujisawa Pharmaceutical Co., Ltd. Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them
JPH11171886A (ja) 1997-12-08 1999-06-29 Mitsui Chem Inc アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
EP1452530A4 (en) * 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
IL162243A0 (en) 2001-12-20 2005-11-20 Wyeth Corp Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US20070053831A1 (en) 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
AU2003304416A1 (en) 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
CN101384555A (zh) 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 新的氨基醇取代的芳基二氢异喹啉酮类、其制备方法以及其作为药物的用途
BRPI0716583A2 (pt) * 2006-08-24 2013-10-01 Australian Nuclear Science Tec ligandos fluorados para marcar recptores de benzodiazepina perifÉricos
JP5190893B2 (ja) * 2006-12-25 2013-04-24 国立大学法人東北大学 ベンゾキサゾール誘導体
US7858803B2 (en) * 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
KR101469275B1 (ko) 2007-06-01 2014-12-08 재단법인서울대학교산학협력재단 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물
WO2009042907A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US20090123373A1 (en) * 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
US20110076230A1 (en) * 2008-05-30 2011-03-31 Barrow James C Novel Substituted Indoles
WO2009155017A2 (en) * 2008-05-30 2009-12-23 Merck & Co., Inc. Novel substituted azabenzoxazoles
WO2010051196A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
PL2414369T3 (pl) 2009-04-02 2016-04-29 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Pochodne imidazo[2,1-b][1,3,4]tiadiazolu
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物
WO2012007510A1 (en) * 2010-07-14 2012-01-19 Bayer Pharma Aktiengesellschaft Compounds for binding and imaging amyloid plaques and their use
JP5824517B2 (ja) 2010-11-30 2015-11-25 武田薬品工業株式会社 二環性化合物
CN102391260B (zh) * 2011-09-29 2014-12-10 上海交通大学 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途
SG11201406759YA (en) * 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9370588B2 (en) * 2013-01-04 2016-06-21 University Of Massachusetts Luciferin amides
GB201306248D0 (en) * 2013-04-05 2013-05-22 Ucl Business Plc Compounds and their uses
CA2917267C (en) * 2013-07-17 2021-12-28 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
CA2959501C (en) * 2014-08-29 2023-10-10 Chdi Foundation, Inc. Probes for imaging huntingtin protein
KR102410733B1 (ko) 2014-08-29 2022-06-20 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴 단백질을 영상화하기 위한 프로브
US10907197B2 (en) 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
PT3186241T (pt) 2014-08-29 2021-01-08 Chdi Foundation Inc Sondas para imagística de proteína de huntington
RU2721419C2 (ru) 2015-08-28 2020-05-19 СиЭйчДиАй ФАУНДЕЙШН, ИНК. Зонды визуализации белка гентингтина

Also Published As

Publication number Publication date
CN116655618A (zh) 2023-08-29
MX380810B (es) 2025-03-12
JP7126541B2 (ja) 2022-08-26
AU2015308774B2 (en) 2020-03-19
EA035646B1 (ru) 2020-07-21
SI3186233T1 (sl) 2022-04-29
EA201790407A1 (ru) 2017-08-31
MX2021003311A (es) 2021-05-14
BR112017004141A2 (pt) 2017-12-12
PL3186233T3 (pl) 2022-02-28
DK3186233T3 (da) 2021-11-22
AU2015308774A8 (en) 2017-03-23
US20230212190A1 (en) 2023-07-06
CN107108534B (zh) 2023-05-09
EP4006016A3 (en) 2022-11-16
CN116655618B (zh) 2025-12-05
JP2017528519A (ja) 2017-09-28
IL250803B (en) 2021-06-30
EP3186233A4 (en) 2018-05-30
HUE056957T2 (hu) 2022-04-28
US20170283436A1 (en) 2017-10-05
CA2959501C (en) 2023-10-10
US12258355B2 (en) 2025-03-25
US10479802B2 (en) 2019-11-19
WO2016033445A1 (en) 2016-03-03
MX2017002703A (es) 2018-01-16
US11059836B2 (en) 2021-07-13
KR20170046173A (ko) 2017-04-28
US20200102328A1 (en) 2020-04-02
KR102456946B1 (ko) 2022-10-21
ES2898965T3 (es) 2022-03-09
CA2959501A1 (en) 2016-03-03
HRP20211778T1 (hr) 2022-03-18
CN107108534A (zh) 2017-08-29
KR20220148298A (ko) 2022-11-04
JP6817207B2 (ja) 2021-01-20
KR102586736B1 (ko) 2023-10-11
PT3186233T (pt) 2021-12-02
AU2015308774A1 (en) 2017-03-16
SG11201701600QA (en) 2017-03-30
EP3186233B8 (en) 2021-09-29
EP3186233A1 (en) 2017-07-05
EP4006016A2 (en) 2022-06-01
JP2021059576A (ja) 2021-04-15
EP3186233B1 (en) 2021-08-25
IL250803A0 (en) 2017-04-30
BR112017004141B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
BR112017004141B8 (pt) Agente de imagemamento e seu uso
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
IL282304A (en) Topical pharmaceutical compositions
IL270514B (en) Agricultural compositions
BR112017004140A2 (pt) sondas para imageamento de proteína de huntingtina
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
PL3381451T3 (pl) Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
AR112602A1 (es) ANTICUERPOS ANTI-TrkB
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
BR112017001375A2 (pt) agente farmacêutico
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
BR112017008811A2 (pt) métodos para o tratamento de distúrbios renais

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2493 DE 16/10/2018 POR TER SIDO INDEVIDA.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B15V Prolongation of time limit allowed

Free format text: DE ACORDO COM COMUNICADO PUBLICADO NA RPI 2487 DE 04/09/2018, COMUNICADO PUBLICADO NA RPI 2488 DE 11/09/2018 E RESOLUCAO INPI/PR NO 225/2018 FICAM DEVOLVIDOS ATE 14/09/2019 OS PRAZOS VENCIDOS NAS DATAS DIVULGADOS DENTRO DOS COMUNICADOS.

B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2495 DE 30/10/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2676 DE 19/04/2022 QUANTO AO INVENTOR POR ERRO MATERIAL DO REQUERENTE.